<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Agios Pharmaceuticals, Inc.

    Agios Pharmaceuticals, Inc.

    Agios is a biopharmaceutical company passionately committed to applying our scient...

    Agios is a biopharmaceutical company passionate...

    Filing Type:    PU
    Iovance Biotherapeutics, Inc.

    Iovance Biotherapeutics, Inc.

    Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on th...

    Iovance Biotherapeutics (formerly traded as Lio...

    Filing Type:    PU
    Axcella Health Inc.

    Axcella Health Inc.

    Axcella is designing and developing AXA Candidates, compositions of endogenous met...

    Axcella is designing and developing AXA Candida...

    Filing Type:    PU
    Nemucore Medical Innovations, Inc.

    Nemucore Medical Innovations, Inc.

    Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâ...

    Nemucore Medical Innovations is here to bring y...

    Amount Raised:    $92,318.00
    Fundraising Status:    EC
    Filing Type:    CF
    Osmotica Pharmaceuticals plc

    Osmotica Pharmaceuticals plc

    Osmotica Pharmaceuticals plc is a fully-integrated biopharmaceutical company focus...

    Osmotica Pharmaceuticals plc is a fully-integra...

    Filing Type:    PU
    MEI Pharma, Inc.

    MEI Pharma, Inc.

    MEI Pharma (Nasdaq: MEIP) is a San Diego-based late-stage pharmaceutical company f...

    MEI Pharma (Nasdaq: MEIP) is a San Diego-based ...

    Filing Type:    PU
    Onconova Therapeutics, Inc.

    Onconova Therapeutics, Inc.

    Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused o...

    Onconova Therapeutics, Inc. is a Phase 3-stage ...

    Filing Type:    PU
    Replimune Group, Inc.

    Replimune Group, Inc.

    Cancer is one of the most difficult diseases to treat. It is constantly changing, ...

    Cancer is one of the most difficult diseases to...

    Filing Type:    PU
    Morphic Holding, Inc.

    Morphic Holding, Inc.

    Morphic Therapeutic is leading the development of a new generation of oral integri...

    Morphic Therapeutic is leading the development ...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.